CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer
Crossref DOI link: https://doi.org/10.1007/s10549-015-3349-8
Published Online: 2015-04-02
Published Print: 2015-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Conley, Sarah J.
Baker, Trenton L.
Burnett, Joseph P.
Theisen, Rebecca L.
Lazarus, Douglas
Peters, Christian G.
Clouthier, Shawn G.
Eliasof, Scott
Wicha, Max S.
Text and Data Mining valid from 2015-04-01